Catalyst Pharmaceuticals, Inc. (CPRX) is a Biotechnology company in the Healthcare sector, currently trading at $26.19. It has a SharesGrow Score of 92/100, indicating a strong investment profile with 6 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of CPRX = $50.75 (+93.8% from the current price, the stock appears undervalued). Analyst consensus target is CPRX = $33 (+26% upside).
Valuation: CPRX trades at a trailing Price-to-Earnings (P/E) of 14.4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.87.
Financials: revenue is $589M, +43.1%/yr average growth. Net income is $214M, growing at +48.7%/yr. Net profit margin is 36.4% (strong). Gross margin is 85.2% (+1.3 pp trend).
Balance sheet: total debt is $3M against $954M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 6.08 (strong liquidity). Debt-to-assets is 0.3%. Total assets: $1.1B.
Analyst outlook: 15 / 16 analysts rate CPRX as buy (94%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 84/100 (Pass), Growth 100/100 (Pass), Past 100/100 (Pass), Health 100/100 (Pass), Moat 66/100 (Partial), Future 94/100 (Pass), Income 100/100 (Pass).
